Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Ruff on the Timing of CRC Treatment With Aflibercept

October 28th 2013

Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the decision regarding the timing of treatment with aflibercept for patients with colorectal cancer.

Side Effect Management With Corticosteroids

October 27th 2013

The Role of Patient Education in Side Effect Management

October 27th 2013

Managing BRAF Inhibitor Associated Skin Toxicity

October 27th 2013

The Nurse's Role in Managing Skin Toxicity

October 27th 2013

Managing mTOR Inhibitor Induced Adverse Events

October 27th 2013

Interdisciplinary Approach to Managing Skin Toxicities

October 27th 2013

Managing Treatment-Related Hand-Foot Skin Reaction

October 27th 2013

Managing BCR-ABL Inhibitor Associated Skin Rash

October 27th 2013

Managing Angiogenesis Inhibitor Related Skin Toxicity

October 27th 2013

Anticipatory Coping in Patients Treated With EGFR Inhibitors

October 27th 2013

Managing EGFR Inhibitor Associated Skin Toxicity

October 27th 2013

Dr. Peeters on the Utility of Aflibercept in CRC

October 22nd 2013

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses the utility of aflibercept in patients with advanced colorectal cancer.

Dr. Tabernero on New Characterizations in CRC

October 18th 2013

Josep Tabernero, MD, PhD, of Vall d'Hebron University Hospital, Barcelona, discusses new characterizations of colorectal cancer.

Dr. Ruff on Aflibercept in Elderly Patients With CRC

October 9th 2013

Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses treating elderly patients with colorectal cancer with aflibercept.

Matching Ostomy Pouching Systems to Patient Need

October 7th 2013

The American Cancer Society estimates that in 2013, 142,820 individuals in the United States will be diagnosed with colorectal cancer and 72,570 with bladder cancer

Dr. Ruff on Prior Bevacizumab in the VELOUR Trial

October 4th 2013

Paul Ruff, MD, director of medical oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the analysis of prior bevacizumab in the VELOUR trial in patients with metastatic colorectal cancer.

Dr. Yoshino on U3-1565 and TAS-102 in Colorectal Cancer

October 2nd 2013

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses U3-1565 and TAS-102, two agents used to treat colorectal cancer.

OS Comparable for Panitumumab and Cetuximab in KRAS Wild-Type mCRC

September 29th 2013

Panitumumab proved noninferior to cetuximab in extending overall survival in patients with chemorefractory KRAS wild-type metastatic colorectal cancer.

Personalized Medicine in Colorectal Cancer

September 29th 2013